Percutaneous transhepatic portal vein stenting for malignant @entity6315 secondary to recurrent perihilar XXXX .

@entity1 @entity101 @entity5 @entity850 @entity6315
BACKGROUND: Transhepatic portal vein (PV) stenting has been shown to be one of the most important treatments for @entity1 with @entity6315 caused by @entity5 . METHODS: Ten consecutive @entity1 with @entity6315 caused by the recurrence of a perihilar @entity5 underwent transhepatic PV stenting. A self-expandable metallic stent was deployed at the @entity850 site. The @entity1 were retrospectively analyzed with regard to the procedure, complications, and survival after the stent placement. RESULTS: The median interval between the primary resection and the PV stenting was 22   months. The initial hepatic resection was a left trisectionectomy with caudate lobectomy in seven @entity1 , a left hepatectomy with caudate lobectomy in one @entity1 , a right anterior sectionectomy with caudate lobectomy following a left hepatectomy in one @entity1 and a partial liver resection in one @entity1 . The angle of the PV around the @entity850 was greater in the @entity1 with @entity6315 located in the right posterior PV. Eight @entity1 with successful PV stent placement were able to receive anticancer treatment, with a median survival of 14   months. The remaining two @entity1 without successful PV stent placement survived less than 6   months. CONCLUSIONS: Portal vein stenting might offer relief from the symptoms associated with PV @entity101 and the opportunity for sustainable anticancer therapy in @entity1 with recurrent perihilar @entity5 .
